Baird R W Upgrades Vor Biopharma (NASDAQ:VOR) to “Strong-Buy”

Vor Biopharma (NASDAQ:VOR) was upgraded by equities researchers at Baird R W from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other research analysts have also recently weighed in on VOR. Zacks Research cut shares of Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday. Wedbush reiterated an “outperform” rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $20.00 to $64.00 in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $77.83.

Vor Biopharma Price Performance

Shares of VOR opened at $29.06 on Wednesday. The stock has a fifty day simple moving average of $36.80. Vor Biopharma has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The company has a market capitalization of $199.06 million, a PE ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Insider Activity

In other news, major shareholder Reprogrammed Interchange Llc sold 33,668 shares of the business’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $30.32, for a total transaction of $1,020,813.76. Following the completion of the sale, the insider directly owned 1,278,118 shares of the company’s stock, valued at approximately $38,752,537.76. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 1,117,860 shares of company stock worth $24,894,078 over the last ninety days. 0.45% of the stock is currently owned by insiders.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in Vor Biopharma in the second quarter worth about $66,000. Goldman Sachs Group Inc. lifted its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares during the period. Jane Street Group LLC purchased a new stake in Vor Biopharma in the first quarter worth about $140,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma in the first quarter worth about $100,000. Finally, Money Concepts Capital Corp lifted its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after acquiring an additional 26,535 shares during the period. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.